Proteomics Services
GENEWIZ Proteomics services offer comprehensive Olink® proteomics panels and Alamar NULISA™ proteomics panels. Proteomics, the study of proteins, provides a comprehensive picture of disease phenotypes and mechanisms at the functional site. Through proteomics at a population scale, scientists can identify causal proteins, uncover novel pathways, and discover potential therapeutic targets. This holistic approach has the potential to revolutionize drug development.
Should I choose olink or nulisa?
While both Olink and NULISA utilize dual antibody barcoding, the targets vary substantially between platform. Which assay you choose will depend on the goal of your study and your key targets of interest.
Technology Comparison
| Proteomics Platform | Recognition | Signal Mechanism | Readout & Quantitation | Sensitivity Floor | Sample Volume | Best Fit |
|---|---|---|---|---|---|---|
| Alamar NULISA | Dual antibody pair | Sequential capture and release with proximity ligation |
NGS (relative or absolute quantitation): NULISA Assays qPCR (relative or absolute quantitation): NULISAqpcr™ Custom Assays |
Attomolar, validated for sub-pg/mL targets | 40 µL | Neurodegeneration biomarkers, low-abundance target detection, longitudinal monitoring |
| Olink Proximity Extension™ Assay (PEA) | Dual antibody pair | Proximity extension with oligonucleotide hybridization |
NGS (relative quantitation): Explore, Reveal qPCR (relative or absolute quantitation): Target |
Femtomolar to picomolar, panel dependent | 40 µL | Discovery, broad biomarker surveys, large cohort screens |
Applications of Proteomics
-
Drug Target Identification & pQTLS
-
Biomarker Analysis & Screening
-
Patient Stratification
-
Predicting Drug Response
Features and Benefits
-
Certified Service Provider
Global CSP for Olink and NULISA assays
-
Sample and Material Management
Offering storage and transport of your samples supported by a strong European local presence
-
Fast Turnaround
Flexible turnaround times to suit your needs, whether you need expedited results or a more relaxed timeline
-
CAP and CLIA Processing
Processing available in our GCP- compliant CLIA and CAP laboratory for clinical applications
Technical Resources
-
Webinar │ Beyond the Genome: Revolutionizing Health with Population-Scale Proteomics and Biomarker Discovery
In this webinar, co-hosted with Olink, discover the role of proteomics in advancing personalized medicine. Our guest speaker, Haythem Latif, Ph.D., provides insights on the importance of biomarkers and how you can effectively integrate proteome data with large-scale genomic datasets to broaden your understanding of human health. Plus, learn about recent population-scale studies utilizing protein biomarker discovery to go beyond the genome.
-
Blog │ The Power of Proteomics
The landscape of drug development is constantly evolving, fueled by groundbreaking scientific advancements. While genetics has played a central role in understanding diseases, proteomics provides a more comprehensive picture of disease phenotypes and mechanisms. In this blog, discover how researchers and clinicians are using Olink proteomics to reshape the outcomes of their clinical studies.
-
Blog | Olink vs NULISA: Which Should I Choose?
The field of proteomics has evolved significantly in the last decade, with several technologies now available to assay protein biomarkers in clinical studies. In this article, we compare three popular approaches for proteomics – mass spectrometry, ELISA, and the Olink® Proximity Extension Assay (PEA) – and highlight their strengths and limitations.
-
Webinar | Do More with Less: Harnessing the Power of Multiomics from a Single Sample
The -omics era has greatly expanded the repertoire of approaches available for researchers and clinicians to unravel the complexities underpinning human health. In this recording from the GENEWIZ Breakfast Talk at ASHG 2022, Dr. Andrea O’Hara presents a workflow to rapidly produce a diverse set of multiomics results, including genomics, epigenomics, transcriptomics, and proteomics, from a single blood draw.
-
Poster | A Demonstrated Workflow to Unleash the Multiomic Potential of a Single Blood Draw
The multiomics era has greatly expanded the repertoire of approaches available for researchers and clinicians to unravel the complexity underpinning human health. Explore how the GENEWIZ single blood draw multiomics workflow can drive more significant insights and innovation in human health applications.
NGS Platforms
For information on our NGS platforms as well as recommended configurations of your projects, please visit the NGS Platforms page. GENEWIZ does not guarantee data output or quality for sequencing-only projects.
